{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:18:36Z","timestamp":1775063916700,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"PixarBio Corporation"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Opioids remain a mainstay in the treatment of acute and chronic pain, despite numerous and potentially dangerous side effects. There is a great unmet medical need for alternative treatments for patients suffering from pain that do not result in addiction or adverse side effects. Anticonvulsants have been shown to be effective in managing pain, though high systemic levels and subsequent side effects limit their widespread usage. Our goal was to determine if the incorporation of an anticonvulsant, carbamazepine, into a biodegradable microparticle for local sustained perineural release would\u00a0be an efficacious analgesic following a peripheral injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following induction of the chronic constriction injury model in Sprague\u2010Dawley rats, mechanical allodynia testing was performed using von Frey filaments and thermal allodynia was evaluated using the Hargreaves method. Histology and blood work were performed to evaluate toxicity as well as to monitor drug and metabolite presence over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 2\u2010fold increase in hindpaw withdrawal thresholds in animals receiving carbamazepine\u2010loaded microparticles relative to controls was observed for up to 14\u00a0days after treatment. Drug and metabolite had a peak blood concentration of 54.7\u00a0ng\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>and dropped off exponentially to &lt;\u00a05\u00a0ng\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>over a few days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This formulation reduced systemic exposure to carbamazepine over 1,000\u2010fold relative to traditional analgesic dosing regimens. This 2\u2010component drug delivery system has been specifically engineered to release a controlled amount of carbamazepine over a 14\u2010day period, providing significant pain relief with no toxicological or observable adverse events via behavioral or histochemical analysis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12705","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T23:22:26Z","timestamp":1525389746000},"page":"1024-1035","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Opiate\u2010Free Pain Therapy Using Carbamazepine\u2010Loaded Microparticles Provides Up to 2 Weeks of Pain Relief in a Neuropathic Pain Model"],"prefix":"10.1111","volume":"18","author":[{"given":"Haining","family":"Dai","sequence":"first","affiliation":[{"name":"PixarBio Corporation Salem New Hampshire U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-1927","authenticated-orcid":false,"given":"Dana M.","family":"Tilley","sequence":"additional","affiliation":[{"name":"PixarBio Corporation Salem New Hampshire U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greici","family":"Mercedes","sequence":"additional","affiliation":[{"name":"PixarBio Corporation Salem New Hampshire U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Doherty","sequence":"additional","affiliation":[{"name":"PixarBio Corporation Salem New Hampshire U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitabh","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care Memorial Sloan Kettering Cancer Center New York City New York U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neel","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Weill Cornell Medical College New York City New York U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer","family":"Khalil","sequence":"additional","affiliation":[{"name":"PixarBio Corporation Salem New Hampshire U.S.A."},{"name":"Department of Neurosurgery University of California Irvine Irvine California U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Holzhaus","sequence":"additional","affiliation":[{"name":"PixarBio Corporation Salem New Hampshire U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis M.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"PixarBio Corporation Salem New Hampshire U.S.A."},{"name":"Frank Reynolds Corporation Salem New Hampshire U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200010000-00038"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1351138"},{"key":"e_1_2_7_4_1","first-page":"208","article-title":"Availability and utilization of opioids for pain management: global issues","volume":"14","author":"Manjiani D","year":"2014","journal-title":"Ochsner J"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.30"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200203000-00019"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000177099.28914.A7"},{"key":"e_1_2_7_8_1","volume-title":"Opioid Addiction: 2016 Facts & Figures","author":"American Society of Addiction Medicine","year":"2016"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e318277a270"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/bean.2003.0275"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.03.017"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.930436"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-9185.83672"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeu202"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e328330373a"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e32833fad0a"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2014.10.002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181c6316e"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/AIA.0b013e31820e4a49"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199606000-00017"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31828174a7"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31816c8a48"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.01.043"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4906-539"},{"key":"e_1_2_7_25_1","unstructured":"Pacira Pharmaceuticals Inc. Exparel Prescribing Information.2018: p.17.https:\/\/www.pacira.com\/sites\/default\/files\/inline-files\/EXPAREL_PI_Nerve_Block_Final_4-6-2018.pdf(accessed May 4 2018)"},{"key":"e_1_2_7_26_1","first-page":"249","article-title":"Gabapentin for once\u2010daily treatment of post\u2010herpetic neuralgia: a review","volume":"7","author":"Beal B","year":"2012","journal-title":"Clin Interv Aging"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/631756"},{"issue":"3","key":"e_1_2_7_28_1","first-page":"CD007938","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore RA","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i3.432"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmr.2005.12.006"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aef163"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jobcr.2012.10.002"},{"issue":"1","key":"e_1_2_7_33_1","first-page":"CD005451","article-title":"Carbamazepine for acute and chronic pain in adults","author":"Wiffen PJ","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014814924965"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01387.x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40659-015-0027-6"},{"key":"e_1_2_7_37_1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0026-895X(25)08760-7","article-title":"Modulation of the gamma\u2010aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin","volume":"47","author":"Granger P","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_38_1","first-page":"25","volume-title":"Translational Pain Research: Comparing Preclinical Studies and Clinical Pain Management","author":"Chen L","year":"2006"},{"key":"e_1_2_7_39_1","volume-title":"Handbook of Pain Medicine","author":"Dureja GP","year":"2014"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.09.028"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012944"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.05.001"},{"issue":"1","key":"e_1_2_7_43_1","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.4103\/0975-7406.155921","article-title":"Bupivacaine versus lignocaine as the choice of\u00a0local anesthetic agent for impacted third molar surgery a\u00a0review","volume":"7","author":"Balakrishnan K","year":"2015","journal-title":"J Pharm Bioallied Sci"},{"key":"e_1_2_7_44_1","first-page":"1549","article-title":"Carbamazepine for acute and chronic pain","volume":"73","author":"Buescher JJ","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2010.23.3.215"},{"key":"e_1_2_7_46_1","first-page":"256","article-title":"Analysis of the electroencephalogram and pain characteristic in patients before and after carbamazepine treatment","volume":"62","author":"Music M","year":"2008","journal-title":"Med Arch"},{"key":"e_1_2_7_47_1","first-page":"25","article-title":"Design and evaluation of carbamazepine controlled release drug delivery system","volume":"4","author":"Charulatha R","year":"2012","journal-title":"Int J PharmTech Res"},{"key":"e_1_2_7_48_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/clinchem\/44.5.1085","article-title":"Standards of laboratory practice: antiepileptic drug monitoring","volume":"44","author":"Warner A","year":"1998","journal-title":"Clin Chem"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T03:53:35Z","timestamp":1751601215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/papr.12705"],"URL":"https:\/\/doi.org\/10.1111\/papr.12705","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"2018-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}